WO1993005084A1 - Composition and method for reducing cholesterol concentration - Google Patents

Composition and method for reducing cholesterol concentration Download PDF

Info

Publication number
WO1993005084A1
WO1993005084A1 PCT/AU1992/000471 AU9200471W WO9305084A1 WO 1993005084 A1 WO1993005084 A1 WO 1993005084A1 AU 9200471 W AU9200471 W AU 9200471W WO 9305084 A1 WO9305084 A1 WO 9305084A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclodextrin
polymer
cholesterol
poly
absorbant
Prior art date
Application number
PCT/AU1992/000471
Other languages
English (en)
French (fr)
Inventor
Gurcharn Singh Sidhu
David George Oakenfull
Michael Laurence Rooney
Original Assignee
Commonwealth Scientific And Industrial Research Organisation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific And Industrial Research Organisation filed Critical Commonwealth Scientific And Industrial Research Organisation
Priority to KR1019940700734A priority Critical patent/KR940702517A/ko
Priority to JP5504679A priority patent/JPH06511270A/ja
Priority to EP92919312A priority patent/EP0602149A1/de
Publication of WO1993005084A1 publication Critical patent/WO1993005084A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C7/00—Other dairy technology
    • A23C7/04—Removing unwanted substances other than lactose or milk proteins from milk
    • A23C7/043—Removing unwanted substances other than lactose or milk proteins from milk using chemicals in liquid or solid state, e.g. flocculating, adsorbing or extracting agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
    • A23L5/27—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption
    • A23L5/273—Removal of unwanted matter, e.g. deodorisation or detoxification by chemical treatment, by adsorption or by absorption using adsorption or absorption agents, resins, synthetic polymers, or ion exchangers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/14—Esterification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C08F8/26—Removing halogen atoms or halogen-containing groups from the molecule

Definitions

  • the present invention relates to an absorbent polymer and method using this absorbent polymer for reducing the level of or removing sterols, particularly cholesterol, from blood, plasma, food materials, fatty substances and oils or fats of biological origin.
  • sterols particularly cholesterol
  • Background of the Invention It is widely accepted that serious health risks attach to high plasma cholesterol levels.
  • coronary heart disease is responsible for more than 50,000 deaths every year, and death from coronary heart disease is twice as frequent as death from cancer.
  • Drugs for reducing cholesterol and triglycerides are listed in Table 1.
  • Cholestyramine is the only drug listed in Table 1 which is not absorbed and which does not enter the metabolic pathways of the body. It has been considered safe, even for children with blood cholesterol and lipid disorders.
  • cholestyramine By sequestering bile acids, cholestyramine inhibits their intestinal absorption, thus interrupting the enterohepatic bile acid cycle.
  • the conversion of liver cholesterol into bile acid is increased and the liver then removes cholesterol from the blood by increasing the number of LDL receptors on liver cells.
  • the daily recommended intake of cholestyramine ranges from 20 to 30g daily. Only 10% of the ion-exchange capacity is utilised for binding bile acids, the remaining capacity is capable of binding other anions in the digesta. Thus the drug is not without side effects; the most common being constipation which occurs in 66% of patients. It can also give a feeling of satiety and cause heartburn. Some patients dislike the gritty, sandy mouthfeel and full compliance with this drug has often been questioned. TABLE 1: Drugs for treatment of hyperlipidaemia**
  • Bile acid Cholestyramine Sequesters bile acids sequestrant ( uestran, the intestinal lumen
  • Niacin Nicotinic acid Primary action is on (Vitamin B3) the liver, where it reduces VLDL production. Reduces blood triglycerides and cholesterol.
  • HMG CoA reductase Lovastatin Reduces cholesterol inhibitor Simvasta in (Zocor) synthesis in the
  • Butylphenol Probuco1 (Lorelco) After being incorporated into LDL, increases the latter's removal by liver, through mechanism other than LDL receptor.
  • cholestyramine interferes with the absorption of fat-soluble vitamins.
  • the drug also interferes with the absorption of a variety of medications, such as thiazines, anticoagulants, digitalis and coumarin derivatives.
  • the remaining drugs in Table 1 act by modifying metabolic processes in the body; they lack specificity and are also not without side effects.
  • the long term safety of drugs that inhibit cholesterol synethesis has not been tested as they have only recently been released.
  • ⁇ - cyclodextrin is a cyclic oligosaccharide of seven glucose units.
  • the secondary OH-groups protrude outwardly from the wide edge of the torus-like cyclodextrin molecule while the primary OH-groups are located on the narrower edge.
  • the central cavity is therefore hydrophobic, giving the molecule an affinity for non-polar molecules such as cholesterol; additionally the radius of the cavity is such as to accommodate a cholesterol molecule almost exactly and this confers a highly specific ability to form an inclusion complex with cholesterol and remove it from food emulsions or fats or oils.
  • the fat in milk is emulsified and, being amphiphilic, the cholesterol molecules are concentrated at the surface of the fat globules where they would be accessible to cyclodextrin in an aqueous phase.
  • the amphiphilic cholesterol molecules would be available for complexing with cyclodextrin in an aqueous phase.
  • the present inventors have developed absorbent polymers which are not only very effective in inhibiting the adsorption of cholesterol and bile acid from the intestine but which is also useful for removing cholesterol and other sterols from food materials and from fatty substances of biological origin more efficiently than has hitherto been possible.
  • the present invention consists in an absorbent polymer for use in reducing cholesterol levels, the absorbent polymer comprising an essentially linear polymer in which all or a substantial proportion of the monomer units carry a covalently linked cyclodextrin or modified cyclodextrin molecule.
  • the cyclodextrin or modified cyclodextrin molecules are covalently linked to the monomer units in a manner such that at least 5% and, preferably at least 25%, of the cyclodextrin or modified cyclodextrin molecules are readily accessible for cholesterol complexations.
  • the cholesterol complexation ability of the absorbent polymer is at least 10%, and preferably at least 25%, of that of free cyclodextrin.
  • the cyclodextrin is ⁇ - cyclodextrin, however, ⁇ - cyclodextrin or / - cyclodextrin can also be used.
  • At least 50% of the monomer units carry a covalently linked cyclodextrin or modified cyclodextrin molecule.
  • Figure 1 shows schematic representations of the absorbent polymer of the present invention in which CD is ⁇ , ⁇ or ⁇ cyclodextrin and CDX is modified a, ⁇ or ⁇ cyclodextrin. It can been seen that the polymer falls into four general categories:-
  • Poly (A) in which each or some of the monomer units (A) are covalently linked to ⁇ -cyclodextrin (BCD-A) as shown in figure 1A.
  • the active polymer is a copolymer of (BCD-A) and (B), or (BCD-B), as shown in Figure IB and 1C.
  • the polymers are essentially linear chains, however, there may be occasional cross-links between chains.
  • the absorbent polymer is selected from the group consisting of poly(3 - cyclodextrinacrylate) , poly(/3 - cyclodextringlacturonate) , poly( / 3 - cyclodextrinmethacrylate) , poly(3 - cyclodextringlycidyl ethacrylate) , poly(3 - cyclodextrinvinylchloride), poly(N-/3 - cyclodextrinacrylamide) and copolymers thereof.
  • the phrase "readily available for cholesterol co plexation” means that the cyclodexation molecule is covalently bound to the monomer unit in such a manner that when the polymer is bought into contact with cholesterol containing material that the cholesterol forms a complex with the cyclodextrin molecules. This is to be contrasted with the situation where, due to the nature of the binding of the cyclodextrin molecule, the cyclodextrin molecule is not able to form a complex with cholesterol.
  • the essentially linear polymer should be non-toxic and resistant to digestion by the enzymes of the gastrointestinal tract.
  • the polymers of the present invention could be administered in the treatment of hypercholesterolaemia to adsorb cholesterol or bile acids in the intestine and inhibit their absorption.
  • Cyclodextrins also form complexes with bile acids and inhibit their absorption from the intestine.
  • modified cyclodextrins or cyclodextrins attached to essentially linear polymers provide another potentially safe means of lowering plasma cholesterol by - like cholestyramine - interrupting the enterohepatic bile acid cycle.
  • cholestyramine that cyclodextrins are more specific and would consequently have fewer side effects.
  • the present invention consists in a method of treating hypercholesterolaemia in a subject comprising administering to the subject an effective amount of the absorbent polymer of the first aspect of the present invention.
  • Another adaptation of this invention would be for the treatment of hypercholesterolaemia by the extraction of cholesterol directly from the blood plasma.
  • Blood could be withdrawn from the patient, treated with a suitable form of the absorbent polymer and then returned to the body.
  • Various techniques have been developed for extracorporeal adsorption and removal of harmful substances from blood plasma (Parker and Studebaker, Methods in Enzymology, 137, 466-478, 1988). Typically these techniques use immobilised enzymes or immunoadsorption systems on plasma after separation of the red blood cells. LDL particles rich in cholesterol can be removed using specially prepared immunoadsorption columns which can be regenerated with buffers for reuse.
  • plasma is subjected to a column treatment to remove LDL particles rich in cholesterol (Yokohama, S., Yamamoto, A., Hayashi, R. et al., Jap. Circ. J. 5_1, 1116-1122, 1987).
  • the treated plasma is then recombined with red blood cells and returned to the patient's blood circulation.
  • Both these techniques suffer from serious disadvantages.
  • Valuable proteins, phospholipids and vitamins are lost from the blood plasma in the course of treatment.
  • immunoadsorption columns cannot be heat sterilised and are likely to induce immune reactions to the antibodies which are derived from animal sources to prepare them.
  • the present invention consists in a method of reducing blood cholesterol levels in a subject comprising withdrawing blood from the subject, contacting the blood with the absorbent polymer of the first aspect of the present invention and returning the treated blood to the subject.
  • the blood cells are removed from the blood and the plasma is contacted with the absorbent polymer of the first aspect of the present invention. Subsequently, the blood cells and the treated plasma are recombined and returned to the subject.
  • the cyclodextrin polymers of this invention are capable of meeting the stringent health and safety requirements which would be required for a cholesterol adsorbant for use with blood plasma. Another important advantage is that the polymers selectively remove the LDL cholesterol which is associated with heart disease risk. The protective HDL cholesterol is left behind.
  • a further form of this invention could be used to selectively and specifically extract cholesterol or bile acids from appropriate source materials such as bile (an abattoir waste) .
  • Cholesterol and bile acids are useful substances in their own right, and more so as precursors for synthesis of steroid-based drugs.
  • a suitable form of the adsorbant would extract these materials and they could be recovered selectively by washing with different solvents or solvent mixtures.
  • the absorbent polymer of the present invention may also be used in the removal or reduction of cholesterol and other sterol levels from food materials. Accordingly, in a fourth aspect the present invention consists in a method of removing or reducing the level of cholesterol in the sample comprising contacting the food material comprising contacting the food material with the absorbent polymer of the first aspect of the present invention.
  • the food is a dairy product.
  • the absorbent polymer of the present invention is to be used in removal or reduction of cholesterol from food materials and the like in the same way as treatments using free cyclodextrin
  • the adsorption of cholesterol using the bound cyclodextrin polymer as described in this application is carried out in an aqueous medium.
  • the adsorption takes place at the oil-water interface, so the fat or oil is preferably exposed to the adsorbant in the form of an oil-in-water emulsion, as this maximises the available interfacial area. Since the fat in milk, cream or egg is already in this form such products can be simply exposed to the adsorbant, however some minimal pretreatment, such as homogenisation or dilution may facilitate rapid interaction.
  • the product is exposed to the active polymer by mixing with efficient stirring, allowing time for reaction (10 seconds to 2 hours and preferably 15 minutes) and then separating the polymer by filtration or centrifugation.
  • the product can be passed through a bed of the polymer in particulate form.
  • the temperature can range from 0 C to 60 C and is preferably in the "chilled" range, below 15°C.
  • the adsorption process can be carried out at any temperature at which water is in the liquid phase.
  • the temperature would be kept close to 0 to avoid microbiological spoilage and deterioration of flavour or functional properties.
  • Low temperature would also make the removal of cholesterol by the absorbent polymer more specific and would preclude complex formation with other constituents such as fatty acids, phospholipids and proteins.
  • Other products, such as lard or tallow, might more conveniently be processed at high temperature where the fat is liquid. There is, however, no necessity for the dispersed fat to be above its bulk melting temperature.
  • the adsorptive power of the absorbent polymer of the present invention can be restored by washing through with acetic acid, or other organic acids, alkali solutions or other suitable solvent, which will remove the cholesterol without degrading the adsorbant.
  • the present inventors have also developed novel method of producing the absorbent polymers of the present invention.
  • the present invention consists in a method of producing an absorbent polymer for use in reducing cholesterol levels, the absorbent polymer comprising an essentially polymer in which all or a substantial portion of the monomer units carry a covalent linked cyclodextrin or modified cyclodextrin molecule, the method comprising reacting the cyclodextrin or modified cyclodextrin molecules with monomer units such that the cyclodextrin or modified cyclodextrin molecules are covalently bound to the monomer units and subsequently preliminising the monomer units.
  • the present invention consists in method of producing an absorbent polymer for use in reducing cholesterol levels.
  • the absorbent polymer comprising an essentially linear polymer in which all or a substantial proportion of the monomer units carry a covalently linked cyclodextrin or modified cyclodextrin molecule, the method comprising preliminising the monomer units and subsequently reacting the polymer with cyclodextrin or modified cyclodextrin molecules such that the cyclodextrin or modified cyclodextrin molecules such that the cyclodextrin or modified cyclodextrin molecules are covalently bound to the monomer units.
  • reaction of the cyclodextrin or ' modified cyclodextrin molecules with the monomer units or polymer is carried out in the presence of dicyclohexylcarbodiimide or one, three-diisopropylcarbodiimide.
  • the polymers PCM and PCG were obtained from ⁇ - cyclodextrinmethacrylate and ⁇ - cyclodextringlycidyl- methacrylate respectively as described under preparation No. 4.
  • Example 6 Reaction of Polyacrylic Acid with BCD NH 2 fPC ⁇
  • the emulsion was prepared in isotonic phosphate buffer and contained 14C-labelled Cr-EDTA added to provide a means of monitoring any uptake of water by the adsorbant. It contained cholesterol (0.25 mM) , oleic acid (1.2 mM) , monoolein (6.0 mM) and sodium taurocholate (10.0 mM) (the same cholesterol concentration as in milk) .
  • the emulsion was prepared in isotonic phosphate buffer and contained 14C-labelled Cr-EDTA added to provide a means of monitoring any uptake or intake of water. It contained cholesterol (O.lmM), oleic acid (1.2mM), onolein (6.0mM) and sodium taurocholate (lO.OmM).
  • Male Wistar rats (300-40Og body weight) were used for studying cholesterol absorption in vivo. After anaesthetising the animals with intraperitoneal sodium pentobarbitol (60mg/kg body weight), the abdomen was ' opened by midline incision and two segments (each about 20cm in length) were isolated, one from the upper jejunum and one from the lower ileum. Inflow cannulae were fitted, distal openings were established and the digesta from the lumen of each segment was washed out with isotonic saline at 37 C . The distal openings were closed by ligatures and cholesterol emulsion (4 ml) was injected. The segment was then closed with another ligature and returned to the abdominal cavity.
  • the abdominal wall was closed with surgical clips. After 30 min the cavity was opened, the segments were removed, washed in isotonic saline to remove blood and drained of water on filter paper. The length of each segment was measured and the contents washed into a 25 ml volumetric flask. The concentration of cholesterol remaining was
  • Chromium EDTA labelled with 14C was used as a non-absorbable marker to check for water influx or efflux. Cyclodextrin or its polymers were added to the emulsion for studying their effect on cholesterol absorption.
  • Table 2 Adsorption of cholesterol (nmol/cm/min.) from rat intestinal segments in vivo (means of results obtained from three animals in each treatment) .
  • Plasma treated with BCD contained 0.6% residual BCD but no BCD was detected in PCA treated plasma.
  • PCG contained only 57.02% of cyclodextrin monomers by weight. If it is assumed further that the cavities of all the cyclodextrins attached to PCA and PCG are readily accessible for cholesterol complexation it can be shown that per cyclodextrin monomer the PCA la, PCA-2, PCM 2 and PCG were decidedly more efficient than free cyclodextrin.
  • Cholesterol emulsion (4 ml) was mixed with BCD or PCA (60 mg) and incubated at 40°C for 15 min. then
  • Egg yolk was separated from white and diluted by adding 3 or 4 volumes of 0.4 M NaCl. Pure cyclodextrin or PCA polymer was added (4% w/v), mixed at 15 C for 20 min, cooled in iced water to below 4 C and centrifuged after holding for 30 min. The cholesterol content of the supernatant was determined by using colorimetric method. The results are given in Table 8.
  • Example 19 Regeneration of the Column 3 [ H]-cholesterol adsorbed by the column was eluted by passing 8 ml of isopropanol:acetic acid (3:1 v/v). The elution was carried out at a temperature of 50 C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • External Artificial Organs (AREA)
PCT/AU1992/000471 1991-09-06 1992-09-04 Composition and method for reducing cholesterol concentration WO1993005084A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR1019940700734A KR940702517A (ko) 1991-09-06 1992-09-04 콜레스테롤 농도 저하용 조성물 및 방법
JP5504679A JPH06511270A (ja) 1991-09-06 1992-09-04 コレステロール濃度を低下させる組成物および方法
EP92919312A EP0602149A1 (de) 1991-09-06 1992-09-04 Zusammensetzung und verfahren zur verringerung der cholesterolkonzentration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPK822291 1991-09-06
AUPK8221 1991-09-06
AUPK822191 1991-09-06
AUPK8222 1991-09-06

Publications (1)

Publication Number Publication Date
WO1993005084A1 true WO1993005084A1 (en) 1993-03-18

Family

ID=25644106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1992/000471 WO1993005084A1 (en) 1991-09-06 1992-09-04 Composition and method for reducing cholesterol concentration

Country Status (5)

Country Link
EP (1) EP0602149A1 (de)
JP (1) JPH06511270A (de)
KR (1) KR940702517A (de)
CA (1) CA2116431A1 (de)
WO (1) WO1993005084A1 (de)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
FR2781232A1 (fr) * 1998-07-15 2000-01-21 Centre Nat Rech Scient Polymere reactif utilisable pour la separation et l'adsorption de substances organiques, et materiau le contenant
US6110517A (en) * 1997-08-02 2000-08-29 Se Jong University Method for removing cholesterol from milk and cream
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
WO2004085485A1 (en) * 2003-03-27 2004-10-07 Chirosep Crosslinked three-dimensional polymer network, method for preparing same, support material comprising same and uses thereof
US6884789B2 (en) 1998-07-01 2005-04-26 California Institute Of Technology Linear cyclodextrin copolymers
WO2007013122A1 (en) * 2005-07-28 2007-02-01 Humanitas Mirasole S.P.A. Haemofilters for blood detoxification
WO2008103657A2 (en) * 2007-02-20 2008-08-28 Cellresin Technologies, Llc Combination of substituted cyclodextrin compound and activated carbon
EP2138190A3 (de) * 2002-08-19 2010-05-12 ArtJen Complexus Inc. Zusammensetzungen mit Nahrungsfettkomplexierer und Verfahren zu ihrer Verwendung
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106008865B (zh) * 2016-05-20 2018-06-26 江苏苏博特新材料股份有限公司 一种混凝土裂缝抑制剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844989A (en) * 1988-01-22 1989-07-27 Asterol International Process for the elimination of steroid compounds contained in a substance of biological origin
AU5476890A (en) * 1989-05-10 1990-11-15 Commonwealth Scientific And Industrial Research Organisation Cholesterol removal
AU5511290A (en) * 1989-05-19 1990-11-22 Commonwealth Scientific And Industrial Research Organisation Cholesterol removal from eggs, dairy products and other aqueous emulsions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844989A (en) * 1988-01-22 1989-07-27 Asterol International Process for the elimination of steroid compounds contained in a substance of biological origin
AU5476890A (en) * 1989-05-10 1990-11-15 Commonwealth Scientific And Industrial Research Organisation Cholesterol removal
AU5511290A (en) * 1989-05-19 1990-11-22 Commonwealth Scientific And Industrial Research Organisation Cholesterol removal from eggs, dairy products and other aqueous emulsions

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5840766A (en) * 1993-06-02 1998-11-24 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US6060517A (en) * 1993-06-02 2000-05-09 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5569452A (en) * 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US6110517A (en) * 1997-08-02 2000-08-29 Se Jong University Method for removing cholesterol from milk and cream
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6884789B2 (en) 1998-07-01 2005-04-26 California Institute Of Technology Linear cyclodextrin copolymers
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
FR2781232A1 (fr) * 1998-07-15 2000-01-21 Centre Nat Rech Scient Polymere reactif utilisable pour la separation et l'adsorption de substances organiques, et materiau le contenant
EP2138190A3 (de) * 2002-08-19 2010-05-12 ArtJen Complexus Inc. Zusammensetzungen mit Nahrungsfettkomplexierer und Verfahren zu ihrer Verwendung
EP2641615A3 (de) * 2002-08-19 2014-01-08 SOHO Flordis International Pty Ltd Zusammensetzungen mit Nahrungsfettkomplexierer und Verfahren zu ihrer Verwendung
US8580242B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8518388B2 (en) 2002-09-06 2013-08-27 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US9550860B2 (en) 2002-09-06 2017-01-24 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8680202B2 (en) 2002-09-06 2014-03-25 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8252276B2 (en) 2002-09-06 2012-08-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8314230B2 (en) 2002-09-06 2012-11-20 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8389499B2 (en) 2002-09-06 2013-03-05 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8399431B2 (en) 2002-09-06 2013-03-19 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8404662B2 (en) 2002-09-06 2013-03-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8475781B2 (en) 2002-09-06 2013-07-02 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8609081B2 (en) 2002-09-06 2013-12-17 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8603454B2 (en) 2002-09-06 2013-12-10 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580244B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
US8580243B2 (en) 2002-09-06 2013-11-12 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2004085485A1 (en) * 2003-03-27 2004-10-07 Chirosep Crosslinked three-dimensional polymer network, method for preparing same, support material comprising same and uses thereof
WO2007013122A1 (en) * 2005-07-28 2007-02-01 Humanitas Mirasole S.P.A. Haemofilters for blood detoxification
EP1752171A1 (de) * 2005-07-28 2007-02-14 Istituto Clinico Humanitas Hämofilter zur Entgiftung von Blut
US8497365B2 (en) 2007-01-24 2013-07-30 Mark E. Davis Cyclodextrin-based polymers for therapeutics delivery
US9610360B2 (en) 2007-01-24 2017-04-04 Ceruliean Pharma Inc. Polymer drug conjugates with tether groups for controlled drug delivery
WO2008103657A2 (en) * 2007-02-20 2008-08-28 Cellresin Technologies, Llc Combination of substituted cyclodextrin compound and activated carbon
WO2008103657A3 (en) * 2007-02-20 2008-11-20 Cellresin Tech Llc Combination of substituted cyclodextrin compound and activated carbon
US10323131B2 (en) 2007-02-20 2019-06-18 Cellresin Technologies, Llc Combination of substituted cyclodextrin compound and activated carbon
US11464871B2 (en) 2012-10-02 2022-10-11 Novartis Ag Methods and systems for polymer precipitation and generation of particles

Also Published As

Publication number Publication date
EP0602149A1 (de) 1994-06-22
KR940702517A (ko) 1994-08-20
JPH06511270A (ja) 1994-12-15
CA2116431A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
WO1993005084A1 (en) Composition and method for reducing cholesterol concentration
Simkin Oral zinc sulphate in rheumatoid arthritis
US5063210A (en) Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US6245753B1 (en) Amphiphilic polysaccharide derivatives
EP0465508B1 (de) Arzneimittel für insulinresistente diabetiker
JPH04503950A (ja) 平滑筋細胞増殖のインヒビターとしてのヘパリン断片
JP2012067119A (ja) サトウキビ・ワックスから得られる第一級脂肪酸の混合物
Barnard et al. Bile acids and vitamin A absorption in man: the effects of two bile acid-binding agents, cholestyramine and lignin
Gafurovich et al. Modified method of plasmapheresis in the treatment of patients with purulent cholangitis
JPH04235130A (ja) マグネシウム−ピリドキサール−５’−ホスフェート−グルタミネートを含む、血管損傷に起因する疾患を予防するための医薬
JP3541007B2 (ja) 両親媒性ポリサッカリド誘導体
US5484777A (en) Pancreatic cholesterol esterase inhibitor
JPH06503305A (ja) 抗ｈｉｖ−１剤としてのデキストリン硫酸とその組成体
AU2555692A (en) Composition and method for reducing cholesterol concentration
US6447812B1 (en) Chemical composition for aiding the absorption, binding and elimination of undigested fat
JPH06199695A (ja) 糖尿病改善治療剤
JPS6154389B2 (de)
Wiggins et al. The origin of faecal fat.
Gordon et al. Abnormal intestinal bile acid distribution in azotaemic man: a possible role in the pathogenesis of uraemic diarrhoea.
US4401430A (en) Method of and apparatus for detoxifying mammalian hosts
KR20010034013A (ko) 지방-결합성 중합체
JP2655592B2 (ja) 極めて高分子量の硫酸化多糖類の製造方法
JPH06199692A (ja) 白内障改善治療剤
US5800809A (en) Non-crosslinked acrylic polymers and non-crosslinked anion exchange resins
EP0393190A4 (en) Copolymers of vinyl alcohol with vinyl acetate, cross-linked by glutaric dialdehyde, method of obtaining them and a phramaceutical preparation based thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2116431

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992919312

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992919312

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1994 204258

Country of ref document: US

Date of ref document: 19940808

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1992919312

Country of ref document: EP